GEN Exclusives

More »

Best of the Web

More »
May 15, 2008 (Vol. 28, No. 10)

Propeller Twist Blog

URL:fjossinet.u-strasbg.fr
  • Interesting software
  • Narrow focus
From Fabrice Jossinet, an assistant professor at the Université Louis Pasteur in Strasbourg, comes this blog dealing with Sequence to Structure (S2S)—a software to “display, manipulate, and interconnect RNA data from the sequence to the structure.” For the uninitiated, this may be a little vague, so I’ll try to interpret. The aim here is to provide RNA researchers with relevant structure information. RNA of course is very different from DNA in several respects. Most of these derive from alternative base pairings enabled by replacing T with U, the 2´ oxygen of ribose (not in deoxyribose), and the usually single-stranded nature of RNA. As a result of these differences, there are a lot more considerations to predicting RNA structure over DNA structure. Indeed, RNA can form much more elaborate 3-D structures than duplex DNA. S2S is written in Java to facilitate cross-platform usage and currently runs on Linux and Mac OSX systems. At the site, visitors can download the software for free and learn a lot more about it than I can describe in this limited space. Definitely worth a look if you’re interested in RNA structure.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?